MBBCh MA(Oxon) MRCS MPH
Academic Clinical Fellow in Primary Care
Emma works within the Interdisciplinary Research in the Health Sciences Group. She studied Medicine at the University of Oxford and then completed Academic Foundation Training in Bristol before starting training in plastic and reconstructive surgery in Oxford. In 2017 she was awarded a Frank Knox Fellowship to complete a Master's in Public Health at the T.H. Chan School of Public Health, Harvard University before returning to Oxford to take up her current post as an NIHR-funded Academic Clinical Fellow. She also works part time as a salaried GP at Eynsham Medical Group and teaches Primary Care to 5th year medical students.
She has an interest in narrative medicine and stories as well as social and community interventions within primary care. Her ACF work has involved conducting a mixed-methods evaluation of a Connecting Communities initiative and she has been part of a team carrying out a large qualitative study on the lived experiences of long Covid. She is currently a Principal Investigator on the SPIKE1 community clinical trial of Camostat for use in Covid-19 infection and is developing her interest in long Covid through two studies - a qualitative exploration of the neuropsychiatric symptoms seen in the condition and a study exploring underlying changes to the metabolome in long Covid patients and other convalescent inflammatory conditions.
Why do GPs rarely do video consultations? qualitative study in UK general practice
Greenhalgh T. et al, (2022), British Journal of General Practice, 72, E351 - E360
Erratum: Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion (Trials (2021) 22 1 (550))
Halford S. et al, (2022), Trials, 23
'I can't cope with multiple inputs': a qualitative study of the lived experience of 'brain fog' after COVID-19
Callan C. et al, (2022), BMJ open, 12
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
Halford S. et al, (2021), Trials, 22
Long Covid – The illness narratives
Rushforth A. et al, (2021), Social Science and Medicine, 286